NCT00559845 A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer Status COMPLETED Phase PHASE2
NCT00559715 Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab Status UNKNOWN Phase PHASE3
NCT00557713 XELOX+Bevacizumab Followed by Capecitabine+Bevacizumab+Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma Status UNKNOWN Phase PHASE2
NCT00556348 Intravitreal Bevacizumab for Choridal Neovascularization Secondary to Age-Related Macular Degeneration Status COMPLETED Phase PHASE4
NCT00556205 Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma Status WITHDRAWN Phase PHASE2
NCT00553800 Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer Status COMPLETED Phase PHASE2
NCT00550927 Enzastaurin and Bevacizumab in Treating Patients With Locally Advanced or Metastatic Cancer Status COMPLETED Phase PHASE1
NCT00550537 Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Status COMPLETED Phase PHASE2
NCT00548548 A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer Status COMPLETED Phase PHASE3
NCT00548418 Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer Status COMPLETED Phase PHASE2
NCT00548197 Preoperative Injection of Bevacizumab Prior to Vitreoretinal Surgery in Diabetic Tractional Retinal Detachment Status COMPLETED Phase PHASE1
NCT00546156 Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer Status COMPLETED Phase PHASE2
NCT00545077 Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women Status COMPLETED Phase PHASE3
NCT00544700 Bevacizumab in Treating Patients Who Have Undergone First-Line Therapy for Metastatic Colorectal Cancer Status TERMINATED Phase PHASE3
NCT00544011 Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Status UNKNOWN Phase PHASE2
NCT00543842 Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer Status COMPLETED Phase PHASE1
NCT00541125 G-CSF in Preventing Neutropenia During First-Line Treatment With Chemotherapy and Bevacizumab in Patients With Metastatic Colorectal Cancer Status COMPLETED Phase PHASE2